According to @aubreydegrey Unity Biotech has obtained $300 million in funding and is valued at nearly one billion dollars, in spite of its very early stage in clinical development. This showcases the incredible excitement in longevity science. @longevityleader@UnityBiotech
Joe Nadeau and I described the fact that mouse experimentation will remain essential for human biology and in particular for drug discovery in @NatRevDrugDisc entitled “The virtuous cycle of human genetics (=observation) and mouse models (=experimentation) in drug discovery".
Intriguing idea that human late life mortality plateaus are due to artefacts (people lying about their age) or errors. The obvious issue, however, is that decreasing mortality at late ages is also observed in laboratory animals, which can't be explained by such errors.
Last Nov, Daniel attended the 4th Eurosymposium on Healthy Ageing @EHA2018 in Brussels, where he shared our latest advances on nanoparticles targeting senescent cells & was interviewed by the Life Extension Advocacy Foundation 👨💼 Check it out here https://t.co/yfcN6XKYjA
Stanley Qi with a “Moore’s Law” style graph on the rate of improvement in cost of genome editing technology. Predicts about time for a new enzyme system to appear (or be engineered). Probably worth a RT. @stanleyqilab#30yearsofaging